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CDH1 mutation carriers have a strongly increased risk of developing gastric cancer (GC) and lobular breast cancer (LBC).
Clinical data of GC cases and surgical and histological data of prophylactic gastrectomies and mastectomies of all 10 Dutch
CDH1 mutation families were collected. In vitro functional assays were performed to analyze the nature of the newly found
missense mutation c.1748T>G (p.Leu583Arg). Ten different CDH1 mutations were found. Functional assays gave strong
arguments for the pathogenic nature of the p.Leu583Arg mutation. The pedigrees comprised 36 GC cases (mean age 40 years,
range 20–72 years) and one LBC case. Twenty-nine/37 carriers alive, aged 18–61 years, underwent prophylactic gastrectomy.
Invasive GC-foci and premalignant abnormalities were detected in 2 and 25 patients, respectively. In four patients GC/
signetring cell (SRC) foci were diagnosed at preoperative gastroscopy. Long-standing presence of SRCs without progression to
invasive carcinoma was shown in two others. Multifocal LBC/LCIS was found in the two prophylactic mastectomy specimens.
Clefts of lip and/or palate (CL/P) were reported in seven individuals from three families. The age at onset and aggressiveness
of GC is highly variable, which has to be included in counseling on planning prophylactic gastrectomies. The incidence of LBC
is expected to increase and prophylactic mastectomy needs to be considered. The relationship between CL/P and CDH1 needs
further study to inform future parents from hereditary diffuse gastric cancer (HDGC) families adequately.
While the incidence of gastric cancer (GC) has declined dur-
ing the last decades, it remains the second cause of cancer
related death worldwide.1 In contrast to the intestinal type of
GC (IGC), diffuse GC (DGC) has no clear deﬁned risk fac-
tors and its incidence has been stable,2 suggesting that genetic
factors play a more dominant role in DGC.
The far majority of DGCs is characterized by loss of
expression of E-cadherin. E-cadherin is a key cell surface pro-
tein involved in intercellular connection and maintenance of
epithelial integrity and is encoded by the tumor suppressor
gene CDH1.3,4 DGCs have a greater tendency to diffusely
invade the gastric wall and often present at an advanced stage.
A minority of DGCs (1–3%) is seen in families with auto-
somal dominant GC susceptibility.5 Germline E-cadherin
inactivating mutations in the CDH1 gene are responsible for
the development of DGC in approximately 30% of families
with the hereditary diffuse gastric cancer syndrome (HDGC).
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Diagnostic criteria for HDGC are formulated by the Interna-
tional Gastric Cancer Linkage Consortium.6,7 Germline
CDH1 mutations have ﬁrst been described in 1998 by Guil-
ford et al. in three Maori kindreds with multiple DGCs at
very young age.8 Subsequently, different germline mutations
have been identiﬁed in families with different ethnic back-
grounds worldwide.9–14 The lifetime risk (LTR) for GC in
HDGC kindreds is high and is estimated >80%.7 Because of
this high risk and the restricted value of current surveillance
modalities, prophylactic gastrectomy is recommended as the
treatment of choice in CDH1 mutation carriers in preventing
advanced GC. In almost all resected stomachs of asymptom-
atic CDH1 mutation carriers multiple foci of signet ring cells
(SRCs) were found.15–17 Female carriers are known to have
an additional high risk of developing lobular breast cancer
(LBC) with LTR of 60% by the age of 80 years, rising from
age 40,6,7,18–21 whereas other tumor sites like colon and pros-
tate might also be associated with HDGC.22,23
In The Netherlands, CDH1 mutation analysis is available
in a clinical setting since 1998. We report on the geno-/phe-
notypical data of all, in total 10, Dutch families with different
pathogenic germline mutations in the CDH1 gene and
describe the functional studies on the pathogenic nature of a
newly found missense mutation. In addition, we summarize
the pathological ﬁndings after prophylactic gastrectomy and
prophylactic mastectomy in mutation carriers in these fami-
lies. We also discuss the issue of counseling on associated
malignancies and prophylactic options and our ﬁnding of
cleft lip with/without palate (CL/P) in a subset of patients.
Material and Methods
Patients and DNA analyses
Individuals from families with multiple GCs and/or GC at
young age were referred to our clinical genetics centers. Fam-
ily details were obtained and led to the suspicion of HDGC
in a subset of families. In index cases from these families,
mutation analysis of the CDH1 gene was performed by PCR
ampliﬁcation of all coding exons including intron/exon boun-
daries, followed by direct sequencing using the bigdye termi-
nator v1.1 cycle sequencing kit (PE Biosystems, Foster City,
CA) and by MLPA analysis using the P08MLPA kit (MRC-
Holland, Amsterdam, The Netherlands) in one laboratory.
In vitro functional assays on the p.Leu583Arg mutation
Human E-cadherin cDNA was cloned in pIRES2-EGFP vec-
tor according to manufacture instructions (Clontech, Takara
Bio) and mutation p.Leu583Arg (c.1748T>G) was induced
by site directed mutagenesis as described previously.24 The
empty vector (Mock) was used as control.
CHO cells were grown in Alfa-MEM medium (Gibco,
Invitrogen) supplemented with 10% fetal bovine serum (FBS;
Gibco, Invitrogen), 1% penicillin-streptomycin (Gibco, Invi-
trogen), in a humiﬁed incubator with 5% CO2 at 37C.
Transient transfection of the above mentioned vectors was
performed with Lipofectamine 2000 (Invitrogen), according
to manufacture instructions, and the transfection efﬁciency
was evaluated by ﬂow cytometry before each experiment,
using GFP ﬂuorescence.
For aggregation assays, trypsinized cells were resssus-
pended in culture medium, 5  104 cells were analyzed by
ﬂow cytometry and 2  104 cells/well were seeded in 96-
well-plate coated with 50 ll of agar solution (100 mg Bacto-
Agar in 15 ml of sterile PBS). The plate was incubated at
37C in a humiﬁed chamber with 5% CO2 for 48 hr and
aggregation was evaluated and photographed in an inverted
microscope (4 magniﬁcation). Experiments always included
triplicates and were repeated ﬁve times.
For invasion assay, 24-well Matrigel invasion chambers (BD
Biocoat) were hydrated, and each chamber was ﬁlled with 5 104
trypsinized cells and incubated for 24 hr at 37C and 5% CO2.
The cells and Matrigel from the upper side of the ﬁlters were
removed with a pre-wet ‘‘cotton swab’’ while cells from the bottom
of the ﬁlter (containing invasive cells) remained untouched. The
ﬁlters were washed in PBS, ﬁxed in ice-cold methanol for 15
minutes and mounted in glass coverslips with Vectashield/DAPI.
The total number of invasive nuclei was counted in a Leica
DM2000 microscope. Experiments were repeated ﬁve times.
Follow-up in CDH1 positive families, histological
evaluation
In families with conﬁrmed HDGC by detection of pathogenic
CDH1 mutations, relatives of index patients were counseled
on HDGC and were offered presymptomatic DNA-analysis.
Based on current knowledge asymptomatic mutation car-
riers were advised to undergo a prophylactic gastrectomy. A
Swiss roll technique25 was used to study the complete mucosa
of the gastrectomy specimens and all abnormalities were
mapped (Figs. 1 and 2). Complete clinical data of all proven/
supposed mutation carriers in these families were collected
and histological specimens of therapeutic and prophylactic
gastrectomy specimens were reviewed by expert pathologists.
Speciﬁcally alterations as described in the context of CDH1
mutation carriers were recorded; the presence of invasive car-
cinoma deﬁned as inﬁltration in the gastric wall beyond the
level of the muscularis mucosae, of clusters of signet ring
cells (SRCs) in the lamina propria <3 mm (also designated
as in situ SRC carcinoma),7 of intraepithelial SRCs with page-
toid spread either in the surface epithelial lining or extending
deeper in the gastric crypt epithelium13 and any additional
mucosal changes were recorded. Furthermore, details were
collected about the surgical procedures and complications of
the individuals who underwent prophylactic gastrectomy.
Results
Description of the 10 CDH1 mutation families
In family A, two cousins died of GC at ages 23 and 34, while their
parents were healthy at that time at an age >60. Several distant
relatives had died of GC at a mean young age. After a pathogenic
CDH1 mutation was found in this family, 11/32 tested relatives
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prophylactic gastrectomy. Three mutation carriers in this family
were born with a cleft lip and palate, an isolated cleft palate and a
subtle lip defect (forme fruste of cleft lip), respectively.
In family B, a CDH1 mutation was found after GC
occurred in four family members at ages from 43 to 56. Sub-
sequently, 16/25 relatives tested positive for this mutation, of
whom 14 underwent a prophylactic gastrectomy.
A female patient in family C died of GC at age 27, while
her father and two of his second degree relatives died of GC
at ages between 50 and 60. Two sisters were shown to be car-
rier of a CDH1 mutation and underwent prophylactic gas-
trectomy. One of them was diagnosed with T2N0M0 DGC
and has no evidence of disease seven years after surgery. CL/
P was reported in three members of this family.
DGC was diagnosed in two sisters in family D from Tur-
kish descent, at ages 37 and 39. Lung cancer and laryngeal
cancer were reported in their father and his brother, both at
age 60. The CDH1 mutation detected in DNA of the index
patients was also found in two children of one of them. Pro-
phylactic gastrectomy is still under consideration.
In family E, a 42-year-old man was diagnosed with GC af-
ter testing positive for a CDH1 mutation and, despite gastrec-
tomy and chemotherapy, he died 19 months after initial diag-
nosis. DNA analysis was performed because of his family
history with a sister, mother and grandmother dead of GC at
ages 26, 43 and 37. His 68-year-old and asymptomatic mater-
nal uncle was tested positive for the CDH1 mutation.
A mother and daughter and a distant relative in family F
died of GC at ages 35, 41 and 72. After her diagnosis LBC at
age 44, a second daughter was shown to be carrier of a
CDH1 mutation, which was also found in a third healthy
daughter. Both underwent prophylactic gastrectomy, com-
bined with prophylactic mastectomy (contralateral/bilateral).
A 20-year-old granddaughter proved to be a mutation carrier
and gave birth to a son with a CLP. The boy’s parents
recently requested counseling on pre-implantation genetic di-
agnosis (PGD) of the CDH1 mutation for future pregnancies.
A 40-year-old female member of the Creole family G
ﬁnally agreed to the proposal of a prophylactic gastrectomy
10 years after the ﬁnding of SRC-foci in her stomach. Gastric
surveillance had been performed because of her family his-
tory with one brother and two sisters dead from GC at ages
32, 22 and 21. Revised histological examination of gastric
biopsies taken seven years before in her niece (daughter of
her deceased brother) showed presence of SRC-foci in these
biopsies. This niece underwent a prophylactic gastrectomy at
age 23. Both gastrectomy specimens showed multiple SRC-
foci in the lamina propria, but no invasive carcinoma. Both
patients proved to be carrier of a CDH1 missense mutation
that was shown to be a pathogenic mutation by in vitro
Figure 1. Swiss roll. Figure 2. Prophylactic resected stomach with 36 SRC-foci (green
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functional assays. Both parents of our ﬁrst index patient died
at ages >80 without a history of malignancies.
In family H, a 41-year-old female was shown to have a
CDH1 mutation after her diagnosis of metastasized GC. Her
father died of GC at age 28. Thus far, her 21-year-old daugh-
ter and a 39-year-old sister tested positive for the CDH1
mutation.
In family I, a CDH1 mutation was found in a 55-year-old
man of Hindustan origin, who was recently diagnosed with
DGC. One half-sister was treated for DGC, two years before
at age 36. A second half-sister and the son of a half-brother
died of DGC at ages 20 and 26, respectively. Their 75-year-
old mother, who turned out to be mutation carrier, was
never diagnosed with cancer. The CDH1 mutation was also
found in the index patient’s affected half-sister alive and in a
second healthy, 50-year-old half-sister. One ﬁrst and one sec-
ond degree relative of his mother were reported to have had
BC and her three brothers died before age 50 of a ‘disease in
the belly accompanied by vomiting blood’.
A pathogenic CDH1 mutation was established in DNA of
a 27-year-old man with DGC in family J. His both parents
were alive without a history of malignancies at ages 72 and
55 and cancer was not reported in their siblings. One distant
relative was treated for testicular cancer at age 40 and died of
GC at age 82. At this moment, no relatives have been tested
for the CDH1 mutation.
Genotypic/phenotypic data of the 10 CDH1 mutation
families
Ten different, of which ﬁve newly described, CDH1 muta-
tions were detected. GC occurred in 36 patients (M/F: 13/
23). Mean age at diagnosis was 40 years (range 20–72 years),
with 27 GCs diagnosed before the age of 50 and 10 of them
before 30 years of age. Twenty-four of 26 conﬁrmed GCs
were classiﬁed as DGC, two of them had clear features of an
intestinal/mucinous GC. In 19 cases, including the IGCs,
SRCs were reported. The IGCs were shown in two patients,
in one proven mutation carrier at age 55 and in a second
deceased patient at age 52, who was a presumed carrier
because of two children being CDH1 mutation carrier, while
this mutation was excluded in DNA of his healthy wife.
Other malignancies than GC are listed in Table 1. CL/P was
reported in seven individuals, of which four mutation carriers
and three untested with 50% risk (Table 1).
Speciﬁcally to investigate the pathogenic effect of the
c.1748T>G (p.Leu583Arg) missense mutation in E-cadherin
function, we performed functional assays in vitro. We found
that CHO cells expressing WT E-cadherin form clear cellular
aggregates, while cells expressing p.Leu583Arg exhibit a scat-
tered pattern, resembling cells expressing the empty vector
(Mock cells) (Fig. 3b). The graph of Figure 3a represents the
percentage of transfection in that experiment. CHO Mock cells
were shown to be invasive using the Matrigel invasion assay.26
When WT E-cadherin was expressed, the levels of cell invasive-
ness decreased, highlighting the role of E-cadherin in invasion
suppression. In all experiments, mutant p.Leu583Arg E-cad-
herin was unable to rescue the invasive behaviour of CHO cells.
Based on the ﬁndings that mutant p.Leu583Arg abrogates E-
cadherin-mediated adhesion and impairs invasion suppression,
we consider this germline CDH1missense mutation pathogenic.
DNA testing and follow-up of mutation carriers
Fifty-eight individuals are known carriers of one of the
CDH1 mutations, 50 by direct testing in blood or archival tis-
sue specimens, eight indirectly as derived from the pedigree.
Of the 39 asymptomatic carriers alive, 29 opted for prophy-
lactic gastrectomy at a mean age of 36 years (18–61 years),
combined with prophylactic mastectomy in two cases.
Prophylactic gastrectomies: Clinical and surgical details
Prophylactic total gastrectomy, with Roux-en-Y-reconstruction,
was performed by laparotomy in 23/29 and by laparoscopic
procedure in 6/29 cases. Treatment related morbidity was
recorded as suture leakage (n ¼ 3), in one patient complicated
by mediastinitis, and bronchopneumonia (n ¼ 2), one result-
ing in ARDS. Four patients required secondary surgical proce-
dures. Three patients underwent re-intervention, respectively,
by endoscopic coagulation and laparotomic resection to com-
plete removal of residual proximal gastric mucosa. Hospitaliza-
tion admission time varied from 5 to 26 days (mean: 11 days).
Prophylactic gastrectomies: Histological findings
All slides of 28 available gastrectomy specimens were revised
for this study. (Pre)malignant changes were seen in 27 of these,
consisting of invasive carcinoma in two patients, intramucosal
carcinomas in 20 patients and intra-epithelial clusters of SRCs
in one patient. In six patients, only very subtle changes were
seen with slightly atypical surface epithelial cells with cytoplas-
mic vacuoles. In one patient, no gastric abnormalities were
observed besides gastritis and intestinal metaplasia at age 42.
The presence or absence of SRCs and/or residual gastric
mucosa in the resection margins was not systematically docu-
mented (Table 2). Gastrointestinal stromal tumours (GISTs)
were found in the stomach and duodenum of two prophylac-
tic treated patients, respectively.
Prophylactic mastectomies: Histological findings
Multiple foci of lobular carcinoma in situ (LCIS) and a 0.5-
mm sized focus of invasive lobular carcinoma were detected
in the contralateral mastectomy specimen of the patient who
was treated for LBC before. Her sister’s mastectomy speci-
mens showed bilateral widespread LCIS.
Discussion
Five CDH1 mutations in the Dutch families were not
reported previously. The other ﬁve mutations were previously
found in more than one unrelated patients who were
reported not to share common haplotypes and are therefore
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Table 1. Genotypic/phenotypic data of the 10 CDH1 mutation families
fam
Mutation (prev.














43 (23–65) 11 4
B c.1565 þ 2dup; Ref. 27 11 M: 1 (47) Abd (50);
PC (57)
F: 3 (43,43,55) U (47)
Me (43)
47 (43–55) 16 12
C c.1135_1137 þ
5delins5; Ref. 28
8 M: 3 (52*, 58, 58) 2 (50%)
F: 1 (27) 1 (mut)
40 (27–52) 1 3
D c.2195G>A (p.Arg732Gln)
Missense; Refs. 9,29
14 M: Lu (60);
La (60)
F: 2 (37,39)
38 (37–39) 2 7
E c.1476_1477del
(p.Arg492fs) Ref. 29
10 M: 1 (42)
F: 3 (26,37,43)
37 (26–43) 1 2
F c.489C>A (p.Cys163X) 4 M: 1 (50%)
F: 3 (35,41,72) LBC (44)
49 (35–72) 2 4
G c.1748T>G
(p.Leu583Arg) Missense
12 M: 1 (32)
F: 2 (21,22)
29 (21–40) 2 9
H c.187C>T (p.Arg63X)
Ref. 23





6 M: 2 (26,55*) BC (50)
BC (age?)
F: 2 (20,36)
35 (20–55) 2 13
J c.55_74del (p.Ser19fs) 1 M: 1 (27)
F:
27
Total 36 (M/F: 13/23) 40 (20–72) 12 37** 58 7
M: male; F: female; GC: gastric cancer (symptomatic/at endoscopy/after prophylactic gastrctomy); BC: breast cancer; LBC: lobular breast cancer;
Abd: ‘cancer in the abdomen’ (unspecified); PC: pancreatic cancer; U: uterine cancer; Me: melanoma; Lu: lung cancer; La: laryngeal cancer; CL: cleft
lip; CL/P: cleft lip and/or palate; mut: mutation carrier; yrs: years; n: number of GC patients;
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c.2195G>A (p.Arg732Gln) missense mutation was proven to
be pathogenic by Brooks-Wilson et al.29
We showed that, in family G, clusters of SRCs were
identiﬁed in prophylactic gastrectomies of two asymptom-
atic individuals carrying the c.1748T>G mutation. The
pathogenic role of this mutation was clearly reproduced
in vitro, emphasizing the role of these studies in predict-
ing the pathogenicity of missense mutations and as a tool
for genetic counseling. The ﬁndings in all Dutch CDH1
mutation families highlight various known and novel
aspects that are important as a guideline for care in fami-
lies at risk.
Phenotypic variation
Although the number of patients in this series is too small to
deﬁne a genotype/phenotype correlation, some observations
should be noted. In accordance with described CDH1 families
worldwide, the majority of GC diagnoses were established
before the age of 50.6 However, our data showed a wide vari-
ability in age at onset (20–72 years) between, but also within
families, with non-penetrance in supposed carriers at an age
older than 75 years in families A, G, and I. Furthermore, GC
was predominantly seen in female patients (M/F: 13/23), con-
sistent with the literature on HDGC but in contrast with IGC
cases in the general population with predominance in males.
All conﬁrmed GCs were DGCs with the exception of
two intestinal GCs, which, however, also contained typical
SRC-components. IGC or intestinal components are
reported within the histological spectrum of HDGC.30 A
latent, nonproliferative, phase of SRCs has been suggested
previously31 and reasoned recently,32 and is now strongly
supported by the presence of SRCs 10 and 7 years prior
to gastrectomy without progression to invasive cancer in
two patients from one family. Remarkable is the variation
in aggressiveness of the disease within this family.
Another notable point is the ﬁnding of only subtle gastric
abnormalities in six prophylactic treated patients and ab-
sence of typical HDGC-related histological ﬁndings in
one patient, all from family B. The six patients showed
predominantly superﬁcial vacuolized cells without the
typical morphology of SRCs, as also described by Fitzger-
ald et al.7 and Carneiro et al.33 for which the relation to
CDH1 mutation carrier status is not fully resolved.
Because of the fact that these subtle lesions are the most
consequent and striking feature in the gastrectomy speci-
mens in this family and frequently the only putative
CDH1-related alteration, it is likely that also these
changes fall within the spectrum of characteristic altera-
tion in CDH1 mutation carriers (Fig. 4). Further study is
planned to investigate if this phenotype may be charac-
teristic for the type of mutation in this family. The
Figure 3. In vitro functional analysis of the germline E-cadherin missense mutation p.Leu583Arg, evaluated by slow aggregation assay. Cells
were transfected with pIRES2-EGFP constructs of empty vector (Mock), WT or p.Leu583Arg human E-cadherin. (a) Transfection efficiency was
evaluated by flow cytometry using GFP expression and the result is presented in the graph. (b) Upon 48 h of incubation in soft agar, cells
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ﬁnding of GISTs in two mutation carriers is presumed to
be coincidental, since no clear correlation between GISTs
and CDH1 was reported in the literature, while Kawa-
nowa et al. showed a high incidence of GISTs in stom-
achs which were resected because of GC (50 microscopic
GISTs in 35 patients).34
Table 2. Prophylactic gastrectomies: histological findings
Indiv M/F Age Histology
(Pre)-malignant
foci (n)
A1 M 49 clusters of SRCs in lamina propria 2
A2 M 46 clusters of SRCs in lamina propria 17
A3 M 45 clusters of SRCs in lamina propria, Hp-gastritis 1
A4 M 43 clusters of SRCs in lamina propria, Hp-gastritis intestinal,
metaplasia GIST in duodenum
4
A5 F 42 clusters of SRCs in lamina propria, intestinal metaplasia/
Barrett
1
A6 M 20 clusters of SRCs in lamina propria 6
A7 M 18 clusters of SRCs in lamina propria 1
A8 F 18 clusters of SRCs in lamina propria 12
A9 F 18 clusters of SRCs in lamina propria, intra-epithelial SRCs 3
B1 M 61 vacuolization of surface epithelium, atrophic gastritis,
intestinal metaplasia, foveal hyperplasia, fundic gland
polyps, pancreatic metaplasia, leiomyomas
<10
B2 M 55 clusters of SRCs in lamina propria 4
B3 F 50 clusters of SRCs in lamina propria 1
B4 M 42 chronic gastritis, intestinal metaplasia, lymphoid aggregation 0
B5 F 40 intra-epithelial SRCs, vacuolization of surface epithelium,
intestinal metaplasia, multiple fundic gland polyps
<10
B6 F 31 intra-epithelial SRCs, vacuolization of surface epithelium, mild
gastritis, areas of subepithelial edema
>30
B7 F 30 vacuolization of surface epithelium, fundic gland polyps,
ectopic gastric mucosa in duodenum
<5
B8 F 31 clusters of SRCs in lamina propria, fundic gland polyp 1
B9 F 30 clusters of SRCs in lamina propria, intra-epithelial SRCs,
vacuolization of surface epithelium, ectopic gastric mucosa
in duodenum
6
B10 M 28 vacuolization of surface epithelium, fundic gland polyps, focal
intestinal metaplasia
<5
B11 M 29 no details (surgery in hospital abroad) ?
B12 F 28 clusters of SRCs in lamina propria 7
B13 F 28 clusters of SRCs in lamina propria 5
B14 M 28 intra-epithelial SRCs <5
C1* F 31 invasive carcinoma 1
C2* F 28 clusters of SRCs in lamina propria, parietal cell hyperplasia 5
F1 F 45 invasive carcinoma, 8 mm, clusters of SRCs in lamina propria,
vacuolization of surface epithelium
1, 37
F2 F 43 clusters of SRCs in lamina propria, intra-epithelial SRCs,
vacuolization of surface epithelium, GIST, ectopic gastric
mucosa in duodenum
1, 10
G1* F 23 clusters of SRCs in lamina propria (since age 16), intestinal
metaplasia
10
G2* F 40 clusters of SRCs in lamina propria (since age 30), intestinal
metaplasia auto-immune atrophic gastritis, G-cell hyperpla-
sia, neuroendocrine cell hyperplasia
>10
M: male; F: female: SRCs: signet ring cells; n: number of foci; Hp: Helicobacter pylori;
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In contrast to the reported excess of LBCs in some
HDGC kindreds,4,6,19,21,35 we observed LBC/LCIS in only two
patients. This is particularly unexpected because of the high
BC incidence in The Netherlands (12.5%)36 and may be
explained by the fact that 18 women died of GC before the
age of 50 and only a few women with a mutation or at 50%
risk of being mutation carrier have reached the age of 50
years without being diagnosed with any type of cancer. The
reported prevalence of LCIS in the general population ranges
from 0.5% to 3.6%. In women diagnosed with LCIS, approxi-
mately 30% will develop an invasive carcinoma, most often
of the ductal type. In the general population, LCIS is most
likely a risk indicator for BC, but it is not itself a true precur-
sor for invasive disease in most patients.37 However, the pres-
ence of multiple foci of LCIS in two CDH1 mutations carriers
suggest a causative relation between the presence of LCIS
and the development of invasive LBC in women carrying a
CDH1 mutation. A small number of malignancies other than
GC and BC were reported. None of these cancer types are
known to be related to CDH1 mutations.
Finally, the occurrence of CL/P in seven individuals, all of
Caucasian origin, in three of our 10 families supports the sug-
gested association of clefts and CDH1 by Frebourg et al.38 They
described two Caucasian CDH1 mutation families with co-
occurrence of CL/P and GC. In human embryos, they showed
expression of CDH1 at weeks 4–6 of embryogenesis, i.e., the
critical stage of lip and palate development. However, clefts
were not reported in 58 other HDGC families with a CDH1
mutation (unpublished data, HDGC consortium Cambridge,
2008), but this may be due to reporting bias. Furthermore, in a
study population of 500 individuals with nonsyndromic clefts
and 500 controls, Letra et al. only observed a borderline associ-
ation of CL/P with CDH1. No cancer data were available for
this cohort.39 Given the fact that CL/P in the general popula-
tion is relatively rare (1–2/1,000 births), the CL/Ps in our
cohort are considered to be related to the CDH1 mutations,
but other unknown factors must have been co-contributing to
the disruption of the lip and palate closure.
Variable penetrance for GC and BC as well as variable
expression of CL/P might be inﬂuenced by the nature of
individual mutations, by modifying genes and by environ-
mental risk factors.19
Implications for clinical practice and genetic counseling
The restricted value of current surveillance modalities for
CDH1 mutation carriers was also emphasized in our study
and supports the need for prophylactic gastrectomy, since
most of the malignant lesions were not detected at pre-opera-
tive gastroscopy. Although prophylactic gastrectomy is
expected to be life-saving, this procedure is not without
short- and long-term risks. Postsurgical complications that
required re-intervention were reported in 4/29 prophylacti-
cally operated patients. This number is low compared to
postoperative morbidity rates of therapeutic gastrectomy. In
most cases, this refers to cancer treatment in mainly elder
patients with co-morbidity and performed with extensive
lymphadenectomy with expected higher risk for complica-
tions.40 Long-term morbidity of prophylactic gastrectomy,
such as nutritional deﬁciencies, food intolerance and diarrhea
as well as impact on psychological functioning is seen in
daily practice and deserves systematic evaluation. Moreover,
long-term study in a larger patient population is needed to
evaluate the oncological effectiveness of prophylactic gastrec-
tomy. This will be largely determined by the absence of tu-
mor cells and absence of normal gastric mucosa in the resec-
tion margins. A frozen section procedure of proximal and
distal margins is warranted during operation and mentioning
of this item in pathology reports is important. The Swiss roll
technique is the designated pathological procedure to enable
localization of lesions precisely.25 Thus far, no recurrent di-
sease or distant metastases were observed in our patient
group.
Regarding to the LBC risk, the IGCLC does not recom-
mend prophylactic mastectomy for all female CDH1 muta-
tion carriers, because of the higher mean age at onset of
BC, which could justify a breast surveillance strategy.6
Since life prognosis is expected to improve after prophy-
lactic gastrectomy, female mutation carriers must be con-
sidered to be at high risk for developing BC after gastrec-
tomy. Because the value of surveillance is also limited in
early detection of LBC, counseling should include the
option of prophylactic mastectomy. For those who choose
not to perform a prophylactic mastectomy, LBC surveil-
lance from age 35 years by annual MRI and mammog-
raphy has been recommended.41
Figure 4. Spectrum of putative and known CDH1-related alterations. (a) Vacuolization of the cytoplasm of surface and foveolar epithelium.
(b) In situ SRC carcinoma with SRC within the basal membrane replacing normal epithelial cells. (c) In situ SRC carcinoma with SRC within
the basal membrane replacing normal epithelial cells and showing pagetoid spread and a focus of early invasive SRC carcinoma. (d)
Clusters of SRCs in the mucosa, consistent with early invasive (intramucosal) carcinoma. (e) Clusters of SRCs in the mucosa, consistent
with early invasive (intramucosal) carcinoma. (f) Invasive poorly differentiated carcinoma, infiltrating beyond the mucosa and into the
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In genetic counseling, an important issue is the preferred
age to perform prophylactic procedures. Regarding gastrec-
tomy, the youngest and mean age of occurrence of GC in the
own family was the main factor in decision making in most
of our patients, together with career planning. Especially
young female mutation carriers have to take their possible
future pregnancies into account in planning of both prophy-
lactic gastrectomy and mastectomy, since postsurgical feeding
and nutritional deﬁciencies could complicate pregnancies and
breast feeding will not be possible. Although Kaurah et al.
showed no adverse outcomes of seven pregnancies in four
women (of whom three CDH1 mutation carriers) after gas-
trectomy and several studies showed no increase of poor
pregnancy outcomes after gastrectomies for reasons other
than cancer, a critical attitude toward the sequence of preg-
nancies and prophylactic surgery is recommended.42–44
In our opinion, there is no reason for informing future
parents about the risk of CL/P in offspring as integral part of
genetic counseling in all HDGC families. However, taking a
family history in HDGC families should include the occur-
rence of CL/P in relatives. In those families positive for CL/P,
current knowledge should be carefully communicated with
counselees, since deﬁnite risks of CL/P are not known.
Finally, the lifelong impact of being CDH1 mutation car-
rier will be, at least for a part of future parents, reason to
consider the possibility of PGD and referral of these couples
to specialized PGD centers may be indicated.
Conclusions
The observed wide variability of age at onset and aggressive-
ness of DGC and the long-standing presence of dormant
SRCs in some patients has to be balanced against the limited
ability of detecting early stages of GC and LBC and the
impact of prophylactic surgery, in the optimal timing of
genetic counseling, testing, and prophylactic surgery for
HDGC family members. In case of prophylactic gastrectomy,
surgeons and pathologists need to be focused on complete
eradication of both malignant cells and normal gastric mu-
cosa. Despite the observed low incidence of LBC, we recom-
mend to discuss the option of prophylactic mastectomy with
female mutation carriers, considering the expected higher
incidence of LBC in the future.
The observed high incidence of CL/P supports the hy-
pothesis that CDH1 mutations are involved in the disturbed
lip and palate closure. This hypothesis needs to be studied in
a larger patient cohort in order to inform future parents
from HDGC-families adequately.
The reported complexity of counseling topics as well as
surgical and pathological procedures and the expected high
physical and psychosocial impact of being a mutation carrier
and undergoing prophylactic interventions emphasize the
need for centralized care for CDH1 mutation carriers, pro-
vided by experts in this ﬁeld working in multidisciplinary
teams. Structured procedures on all aspects of this care are
warranted.
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